image

Circulating Tumor Cells Market Report Scope & Overview:

The Circulating Tumor Cells Market size was estimated USD 11.46 billion in 2023 and is expected to reach USD 31.85 billion by 2031 at a CAGR of 13.63% during the forecast period of 2024-2031. 

Circulating tumor cells (CTC) are cells that travel via the vasculature or lymphatics of a tumor and blood circulations and are moved around the body. CTC tests are used to assist oncologists in determining whether a patient has metastatic breast, prostate, or colorectal cancer.

Circulating Tumor Cells Market Revenue Analysis

MARKET DYNAMICS

DRIVERS

  • Increasing research and development of targeted therapeutics

  • An increase in the prevalence of disorders with multiple chromosomal abnormalities.

The industry is being driven by rising demand for companion diagnostics. Increased R&D of targeted medicines, the development of new biomarkers for diverse illnesses, and an increase in the number of unmet requirements for cancer therapy are boosting the demand for companion diagnostics.

RESTRAIN 

Market Restriction for Circulating Tumor Cells The lack of awareness and adoption of CTCs may stymie industry growth. Many healthcare practitioners and patients are ignorant of the benefits and possible applications of CTC technology due to a variety of problems such as a lack of awareness among healthcare professionals, restricted availability of CTC-based tests, and high costs associated with their deployment. This lack of awareness and comprehension has hampered widespread adoption of CTC-based diagnostics and therapeutics, stifling market growth and progress.

OPPORTUNITY 

  • Government research on CTC technology is ongoing.

Several government organizations, like the American Association of Cancer Research and the American Society of Clinical Oncology, are conducting research on CTC technology to use it as a surrogate marker for determining cancer progression, which is expected to boost market growth.

CHALLENGES

  • The high cost of CTC analysis and detection methods

  • Low awareness and adoption

IMPACT OF RUSSIAN UKRAINE WAR

The Russian-Ukraine war on tumor cells has been harmed. At least 3.0 million Ukrainians have already deserted the country. Critical infrastructure, including hospitals, has been devastated. Children with cancer were hurriedly evacuated to foreign nations to avoid interruptions in their life-saving therapies. Most adults did not have that option. War breeds cancer by delaying detection, preventing treatment, and raising risk. They estimate that a four-month delay in treatment for five common kinds of cancer will result in an excess of 3,600 cancer deaths in the following years. It is vital to develop steps to mitigate the risk as soon as possible.

IMPACT OF ONGOING RECESSION

The COVID-19 pandemic is still evolving, and the extent to which COVID-19 will impact Biocept, Inc.'s business will be determined by future developments that are highly uncertain and cannot be predicted with certainty, such as the disease's ultimate geographic spread, the duration of any outbreaks, travel restrictions and social distancing in the United States and other countries, government funding for COVID-19 testing, business closures or disruptions, and the severity of any outbreaks.

KEY SEGMENTS

By Technology

  • CTC Detection & Enrichment Methods

    • Immunocapture (Label-based)

      • Positive Selection

      • Negative Selection

    • Size-based Separation (Label-free)

      • Membrane-based

      • Microfluidic-based

    • Density-based Separation (Label-free)

    • Combined Methods (Label-free)

  • CTC Direct Detection Methods

    • SERS

    • Microscopy

    • Others

  • CTC Analysis

In 2023, CTC Detection & Enrichment Methods segment is expected to held the highest market share of 65.4% during the forecast period. The availability of various technologies for enriching circulating tumor cells in cancer detection is projected to have a major impact on sector growth throughout the forecast period. Furthermore, positive or negative enrichment of CTCs depending on biological features is projected to hold significant market growth potential. An efficient enrichment method improves sensitivity, selectivity, and yield, ensuring the successful clinical translation of this sector.

By Product

  • Kits & Reagents

  • Blood Collection Tubes

  • Devices or Systems

In 2023, devices or systems segment is expected to held the highest market share of 43.2% during the forecast period. This might be ascribed to the availability of a strong product range along with developments in microfluidics technology. The development of manufactured glass microchips to overcome obstacles and boost technical completeness for mass production is projected to drive segment growth. The introduction of automated tools that minimize the need for extra blood collection tubes reduces the cost of blood collection tubes.

By Specimen

  • Blood

  • Bone Marrow

  • Other Body Fluids

In 2023, blood segment is expected to dominate the market growth of 46.6% during the forecast period. The highest penetration of this specimen type is due to the high quantity of these cells in blood samples as compared to other biospecimens. Approaches for identifying tumor cells in blood samples are significant in contemporary cancer research because they help predict prognosis and determine responsiveness to systemic chemotherapy. However, when paired with microfluidic technology, the utilization of whole blood as a specimen presents a difficulty.

By Application

  • Clinical/ Liquid Biopsy

    • Risk Assessment

    • Screening and Monitoring

  • Research

    • Cancer Stem Cell & Tumorogenesis Research

    • Drug/Therapy Development

Circulating Tumor Cells Market Segmentation Analysis

In 2023, Research segment is expected to dominate the market growth of 73.1% during the forecast period. Cancer metastasis is thought to be facilitated by circulating tumor cells. Counting tumor cells in the bloodstream is currently mostly a research method. Recently, the emphasis has switched to the characterisation and isolation of circulating tumor cells, which can provide considerable prospects in predictive testing research.

REGIONAL ANALYSES

North America held a significant market share growing with a highest CAGR of 35.7% in 2023. The region's significant players include Aviva Biosciences, Apocell, Inc., Advanced Cell Diagnostics, Biocept, Inc., Biofluidica, Inc., and CellTraffix, Inc. These businesses are pursuing various tactics to increase their market share, which is a major contributor to the large share of the U.S. North America is expected to contribute considerably to worldwide market growth due to factors such as rising cancer incidence, product approvals, and expanded R&D initiatives. According to the American Cancer Society, there will be approximately 127,170 lung cancer fatalities and approximately 238,440 new cases of lung cancer diagnosis in 2023. Furthermore, the presence of a cancer-prone population, increased market penetration rates, and technologically improved cancer care infrastructure all contribute to the region's growth.

Asia-Pacific is witness to expand fastest CAGR rate during the forecast period due to significant unmet diagnostic needs and rapidly growing patient knowledge of cancer early detection and risk assessment.

REGIONAL COVERAGE

North America

  • US

  • Canada

  • Mexico

Europe

  • Eastern Europe

    • Poland

    • Romania

    • Hungary

    • Turkey

    • Rest of Eastern Europe

  • Western Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Netherlands

    • Switzerland

    • Austria

    • Rest of Western Europe

Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Vietnam

  • Singapore

  • Australia

  • Rest of Asia Pacific

Middle East & Africa

  • Middle East

    • UAE

    • Egypt

    • Saudi Arabia

    • Qatar

    • Rest of Middle East

  • Africa

    • Nigeria

    • South Africa

    • Rest of Africa

Latin America

  • Brazil

  • Argentina

  • Colombia

  • Rest of Latin America

Key Players

The major key players are QIAGEN, Bio-Techne Corporation, Thermo Fisher Scientific Inc., Precision for Medicine, AVIVA Biosciences, BIOCEPT, Inc., Fluxion Biosciences, Inc., Greiner Bio One International GmbH, Ikonisys Inc., Miltenyi Biotec, Menarini Silicon Biosystems, LineaRx, Inc. (Vitatex, Inc.), STEMCELL Technologies, Inc., and Others.

Bio-Techne Corporation-Company Financial Analysis

Company Landscape Analysis

RECENT DEVELOPMENT

  • Menarini Silicon Biosystems, in July 2023, Menarini Silicon Biosystems announced the launch of its new CELLSEARCH CTC test for small cell lung cancer with the DLL3 biomarker for research usage only in North America and Europe.

  • Thermo Fisher Scientific Inc., in October 2022, Thermo Fisher Scientific Inc. introduced the Gibco CTS DynaCellect Magnetic Separation System (DynaCellect), which enables cell therapy companies to seamlessly transition from process and clinical development to commercial manufacture. This next-generation cell isolation, activation, depletion, and Dynabeads magnetic beads removal equipment offers a scalable, adaptable, automated, and closed system to aid in the optimization of the cell therapy manufacturing process. As a result, the proper cells are separated and production problems are minimized.  

Circulating Tumor Cells Market Report Scope:
Report Attributes Details
Market Size in 2023  US$ 11.46 Billion
Market Size by 2031  US$ 31.85 Billion
CAGR   CAGR of 13.63% From 2024 to 2031
Base Year 2023
Forecast Period  2024-2031
Historical Data  2020-2022
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Technology (CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis)
• By Product (Kits & Reagents, Blood Collection Tubes, Devices or Systems)
• By Specimen (Blood, Bone Marrow, Other Body Fluids)
• By Application (Clinical/ Liquid Biopsy, Research)
Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America)
Company Profiles QIAGEN, Bio-Techne Corporation, Thermo Fisher Scientific Inc., Precision for Medicine, AVIVA Biosciences, BIOCEPT, Inc., Fluxion Biosciences, Inc., Greiner Bio One International GmbH, Ikonisys Inc., Miltenyi Biotec, Menarini Silicon Biosystems, LineaRx, Inc. (Vitatex, Inc.), STEMCELL Technologies, Inc.
Key Drivers • Increasing research and development of targeted therapeutics
• An increase in the prevalence of disorders with multiple chromosomal abnormalities.
Market Opportunity • Government research on CTC technology is ongoing.

 

Frequently Asked Questions

Ans: Circulating Tumor Cells Market size was valued at USD 10.4 billion in 2022.

Ans: The Circulating Tumor Cells Market is expected to grow at 13.4% CAGR from 2023 to 2030.

Ans: According to our analysis, the Circulating Tumor Cells Market is anticipated to reach USD 28.4 billion by 2030.

Ans: Ongoing government research on CTC technology is ongoing.

Ans: Yes, you may request customization based on your company's needs.

TABLE OF CONTENT

1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges

4. Impact Analysis
4.1 Impact of the Ukraine- Russia war
4.2 Impact of ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World

5. Value Chain Analysis

6. Porter’s 5 forces model

7. PEST Analysis

8. Circulating Tumor Cells Market Segmentation, by Technology
8.1 CTC Detection & Enrichment Methods
8.1.1 Immunocapture (Label-based)
8.1.1.1 Positive Selection
8.1.1.2 Negative Selection
8.1.2 Size-based Separation (Label-free)
8.1.2.1 Membrane-based
8.1.2.2 Microfluidic-based
8.1.3 Density-based Separation (Label-free)
8.1.4 Combined Methods (Label-free)
8.2 CTC Direct Detection Methods
8.2.1 SERS
8.2.2 Microscopy
8.2.3 Others
8.3 CTC Analysis

9. Circulating Tumor Cells Market Segmentation, by Product
9.1.1 Kits & Reagents
9.1.2 Blood Collection Tubes
9.1.3 Devices or Systems

10. Circulating Tumor Cells Market Segmentation, by Specimen
10.1 Blood
10.2 Bone Marrow
10.3 Other Body Fluids

11.  Circulating Tumor Cells Market Segmentation, by Application
11.1 Clinical/ Liquid Biopsy
11.1.1 Risk Assessment
11.1.2 Screening and Monitoring
11.2 Research
11.2.1 Cancer Stem Cell & Tumorogenesis Research
11.2.2 Drug/Therapy Development

12. Regional Analysis
12.1 Introduction
12.2 North America
12.2.1 North America Circulating Tumor Cells Market by Country
12.2.2North America Circulating Tumor Cells Market by Technology
12.2.3 North America Circulating Tumor Cells Market by Product
12.2.4 North America Circulating Tumor Cells Market by Specimen
12.2.5 North America Circulating Tumor Cells Market by Application
12.2.6 USA
12.2.6.1 USA Circulating Tumor Cells Market by Technology
12.2.6.2 USA Circulating Tumor Cells Market by Product
12.2.6.3 USA Circulating Tumor Cells Market by Specimen
12.2.6.4 USA Circulating Tumor Cells Market by Application
12.2.7 Canada
12.2.7.1 Canada Circulating Tumor Cells Market by Technology
12.2.7.2 Canada Circulating Tumor Cells Market by Product
12.2.7.3 Canada Circulating Tumor Cells Market by Specimen
12.2.7.4 Canada Circulating Tumor Cells Market by Application
12.2.8 Mexico
12.2.8.1 Mexico Circulating Tumor Cells Market by Technology
12.2.8.2 Mexico Circulating Tumor Cells Market by Product
12.2.8.3 Mexico Circulating Tumor Cells Market by Specimen
12.2.8.4 Mexico Circulating Tumor Cells Market by Application
12.3 Europe
12.3.1 Eastern Europe
12.3.1.1 Eastern Europe Circulating Tumor Cells Market by Country
12.3.1.2 Eastern Europe Circulating Tumor Cells Market by Technology
12.3.1.3 Eastern Europe Circulating Tumor Cells Market by Product
12.3.1.4 Eastern Europe Circulating Tumor Cells Market by Specimen
12.3.1.5 Eastern Europe Circulating Tumor Cells Market by Application
12.3.1.6 Poland
12.3.1.6.1 Poland Circulating Tumor Cells Market by Technology
12.3.1.6.2 Poland Circulating Tumor Cells Market by Product
12.3.1.6.3 Poland Circulating Tumor Cells Market by Specimen
12.3.1.6.4 Poland Circulating Tumor Cells Market by Application
12.3.1.7 Romania
12.3.1.7.1 Romania Circulating Tumor Cells Market by Technology
12.3.1.7.2 Romania Circulating Tumor Cells Market by Product
12.3.1.7.3 Romania Circulating Tumor Cells Market by Specimen
12.3.1.7.4 Romania Circulating Tumor Cells Market by Application
12.3.1.8 Hungary
12.3.1.8.1 Hungary Circulating Tumor Cells Market by Technology
12.3.1.8.2 Hungary Circulating Tumor Cells Market by Product
12.3.1.8.3 Hungary Circulating Tumor Cells Market by Specimen
12.3.1.8.4 Hungary Circulating Tumor Cells Market by Application
12.3.1.9 Turkey
12.3.1.9.1 Turkey Circulating Tumor Cells Market by Technology
12.3.1.9.2 Turkey Circulating Tumor Cells Market by Product
12.3.1.9.3 Turkey Circulating Tumor Cells Market by Specimen
12.3.1.9.4 Turkey Circulating Tumor Cells Market by Application
12.3.1.10 Rest of Eastern Europe
12.3.1.10.1 Rest of Eastern Europe Circulating Tumor Cells Market by Technology
12.3.1.10.2 Rest of Eastern Europe Circulating Tumor Cells Market by Product
12.3.1.10.3 Rest of Eastern Europe Circulating Tumor Cells Market by Specimen
12.3.1.10.4 Rest of Eastern Europe Circulating Tumor Cells Market by Application
12.3.2 Western Europe
12.3.2.1 Western Europe Circulating Tumor Cells Market by Country
12.3.2.2 Western Europe Circulating Tumor Cells Market by Technology
12.3.2.3 Western Europe Circulating Tumor Cells Market by Product
12.3.2.4 Western Europe Circulating Tumor Cells Market by Specimen
12.3.2.5 Western Europe Circulating Tumor Cells Market by Application
12.3.2.6 Germany
12.3.2.6.1 Germany Circulating Tumor Cells Market by Technology
12.3.2.6.2 Germany Circulating Tumor Cells Market by Product
12.3.2.6.3 Germany Circulating Tumor Cells Market by Specimen
12.3.2.6.4 Germany Circulating Tumor Cells Market by Application
12.3.2.7 France
12.3.2.7.1 France Circulating Tumor Cells Market by Technology
12.3.2.7.2 France Circulating Tumor Cells Market by Product
12.3.2.7.3 France Circulating Tumor Cells Market by Specimen
12.3.2.7.4 France Circulating Tumor Cells Market by Application
12.3.2.8 UK
12.3.2.8.1 UK Circulating Tumor Cells Market by Technology
12.3.2.8.2 UK Circulating Tumor Cells Market by Product
12.3.2.8.3 UK Circulating Tumor Cells Market by Specimen
12.3.2.8.4 UK Circulating Tumor Cells Market by Application
12.3.2.9 Italy
12.3.2.9.1 Italy Circulating Tumor Cells Market by Technology
12.3.2.9.2 Italy Circulating Tumor Cells Market by Product
12.3.2.9.3 Italy Circulating Tumor Cells Market by Specimen
12.3.2.9.4 Italy Circulating Tumor Cells Market by Application
12.3.2.10 Spain
12.3.2.10.1 Spain Circulating Tumor Cells Market by Technology
12.3.2.10.2 Spain Circulating Tumor Cells Market by Product
12.3.2.10.3 Spain Circulating Tumor Cells Market by Specimen
12.3.2.10.4 Spain Circulating Tumor Cells Market by Application
12.3.2.11 Netherlands
12.3.2.11.1 Netherlands Circulating Tumor Cells Market by Technology
12.3.2.11.2 Netherlands Circulating Tumor Cells Market by Product
12.3.2.11.3 Netherlands Circulating Tumor Cells Market by Specimen
12.3.2.11.4 Netherlands Circulating Tumor Cells Market by Application
12.3.2.12 Switzerland
12.3.2.12.1 Switzerland Circulating Tumor Cells Market by Technology
12.3.2.12.2 Switzerland Circulating Tumor Cells Market by Product
12.3.2.12.3 Switzerland Circulating Tumor Cells Market by Specimen
12.3.2.12.4 Switzerland Circulating Tumor Cells Market by Application
12.3.2.13 Austria
12.3.2.13.1 Austria Circulating Tumor Cells Market by Technology
12.3.2.13.2 Austria Circulating Tumor Cells Market by Product
12.3.2.13.3 Austria Circulating Tumor Cells Market by Specimen
12.3.2.13.4 Austria Circulating Tumor Cells Market by Application
12.3.2.14 Rest of Western Europe
12.3.2.14.1 Rest of Western Europe Circulating Tumor Cells Market by Technology
12.3.2.14.2 Rest of Western Europe Circulating Tumor Cells Market by Product
12.3.2.14.3 Rest of Western Europe Circulating Tumor Cells Market by Specimen
12.3.2.14.4 Rest of Western Europe Circulating Tumor Cells Market by Application
12.4 Asia-Pacific
12.4.1 Asia Pacific Circulating Tumor Cells Market by Country
12.4.2 Asia Pacific Circulating Tumor Cells Market by Technology
12.4.3 Asia Pacific Circulating Tumor Cells Market by Product
12.4.4 Asia Pacific Circulating Tumor Cells Market by Specimen
12.4.5 Asia Pacific Circulating Tumor Cells Market by Application
12.4.6 China
12.4.6.1 China Circulating Tumor Cells Market by Technology
12.4.6.2 China Circulating Tumor Cells Market by Product
12.4.6.3 China Circulating Tumor Cells Market by Specimen
12.4.6.4 China Circulating Tumor Cells Market by Application
12.4.7 India
12.4.7.1 India Circulating Tumor Cells Market by Technology
12.4.7.2 India Circulating Tumor Cells Market by Product
12.4.7.3 India Circulating Tumor Cells Market by Specimen
12.4.7.4 India Circulating Tumor Cells Market by Application
12.4.8 Japan
12.4.8.1 Japan Circulating Tumor Cells Market by Technology
12.4.8.2 Japan Circulating Tumor Cells Market by Product
12.4.8.3 Japan Circulating Tumor Cells Market by Specimen
12.4.8.4 Japan Circulating Tumor Cells Market by Application
12.4.9 South Korea
12.4.9.1 South Korea Circulating Tumor Cells Market by Technology
12.4.9.2 South Korea Circulating Tumor Cells Market by Product
12.4.9.3 South Korea Circulating Tumor Cells Market by Specimen
12.4.9.4 South Korea Circulating Tumor Cells Market by Application
12.4.10 Vietnam
12.4.10.1 Vietnam Circulating Tumor Cells Market by Technology
12.4.10.2 Vietnam Circulating Tumor Cells Market by Product
12.4.10.3 Vietnam Circulating Tumor Cells Market by Specimen
12.4.10.4 Vietnam Circulating Tumor Cells Market by Application
12.4.11 Singapore
12.4.11.1 Singapore Circulating Tumor Cells Market by Technology
12.4.11.2 Singapore Circulating Tumor Cells Market by Product
12.4.11.3 Singapore Circulating Tumor Cells Market by Specimen
12.4.11.4 Singapore Circulating Tumor Cells Market by Application
12.4.12 Australia
12.4.12.1 Australia Circulating Tumor Cells Market by Technology
12.4.12.2 Australia Circulating Tumor Cells Market by Product
12.4.12.3 Australia Circulating Tumor Cells Market by Specimen
12.4.12.4 Australia Circulating Tumor Cells Market by Application
12.4.13 Rest of Asia-Pacific
12.4.13.1 Rest of Asia-Pacific Circulating Tumor Cells Market by Technology
12.4.13.2 Rest of Asia-Pacific Circulating Tumor Cells Market by Product
12.4.13.3 Rest of Asia-Pacific Circulating Tumor Cells Market by Specimen
12.4.13.4 Rest of Asia-Pacific Circulating Tumor Cells Market by Application
12.5 Middle East & Africa
12.5.1 Middle East
12.5.1.1 Middle East Circulating Tumor Cells Market by country
12.5.1.2 Middle East Circulating Tumor Cells Market by Technology
12.5.1.3 Middle East Circulating Tumor Cells Market by Product
12.5.1.4 Middle East Circulating Tumor Cells Market by Specimen
12.5.1.5 Middle East Circulating Tumor Cells Market by Application
12.5.1.6 UAE
12.5.1.6.1 UAE Circulating Tumor Cells Market by Technology
12.5.1.6.2 UAE Circulating Tumor Cells Market by Product
12.5.1.6.3 UAE Circulating Tumor Cells Market by Specimen
12.5.1.6.4 UAE Circulating Tumor Cells Market by Application
12.5.1.7 Egypt
12.5.1.7.1 Egypt Circulating Tumor Cells Market by Technology
12.5.1.7.2 Egypt Circulating Tumor Cells Market by Product
12.5.1.7.3 Egypt Circulating Tumor Cells Market by Specimen
12.5.1.7.4 Egypt Circulating Tumor Cells Market by Application
12.5.1.8 Saudi Arabia
12.5.1.8.1 Saudi Arabia Circulating Tumor Cells Market by Technology
12.5.1.8.2 Saudi Arabia Circulating Tumor Cells Market by Product
12.5.1.8.3 Saudi Arabia Circulating Tumor Cells Market by Specimen
12.5.1.8.4 Saudi Arabia Circulating Tumor Cells Market by Application
12.5.1.9 Qatar
12.5.1.9.1 Qatar Circulating Tumor Cells Market by Technology
12.5.1.9.2 Qatar Circulating Tumor Cells Market by Product
12.5.1.9.3 Qatar Circulating Tumor Cells Market by Specimen
12.5.1.9.4 Qatar Circulating Tumor Cells Market by Application
12.5.1.10 Rest of Middle East
12.5.1.10.1 Rest of Middle East Circulating Tumor Cells Market by Technology
12.5.1.10.2 Rest of Middle East Circulating Tumor Cells Market by Product
12.5.1.10.3 Rest of Middle East Circulating Tumor Cells Market by Specimen
12.5.1.10.4 Rest of Middle East Circulating Tumor Cells Market by Application
12.5.2. Africa
12.5.2.1 Africa Circulating Tumor Cells Market by country
12.5.2.2 Africa Circulating Tumor Cells Market by Technology
12.5.2.3 Africa Circulating Tumor Cells Market by Product
12.5.2.4 Africa Circulating Tumor Cells Market by Specimen
12.5.2.5 Africa Circulating Tumor Cells Market by Application
12.5.2.6 Nigeria
12.5.2.6.1 Nigeria Circulating Tumor Cells Market by Technology
12.5.2.6.2 Nigeria Circulating Tumor Cells Market by Product
12.5.2.6.3 Nigeria Circulating Tumor Cells Market by Specimen
12.5.2.6.4 Nigeria Circulating Tumor Cells Market by Application
12.5.2.7 South Africa
12.5.2.7.1 South Africa Circulating Tumor Cells Market by Technology
12.5.2.7.2 South Africa Circulating Tumor Cells Market by Product
12.5.2.7.3 South Africa Circulating Tumor Cells Market by Specimen
12.5.2.7.4 South Africa Circulating Tumor Cells Market by Application
12.5.2.8 Rest of Africa
12.5.2.8.1 Rest of Africa Circulating Tumor Cells Market by Technology
12.5.2.8.2 Rest of Africa Circulating Tumor Cells Market by Product
12.5.2.8.3 Rest of Africa Circulating Tumor Cells Market by Specimen
12.5.2.8.4 Rest of Africa Circulating Tumor Cells Market by Application
12.6. Latin America
12.6.1 Latin America Circulating Tumor Cells Market by country
12.6.2 Latin America Circulating Tumor Cells Market by Technology
12.6.3 Latin America Circulating Tumor Cells Market by Product
12.6.4 Latin America Circulating Tumor Cells Market by Specimen
12.6.5 Latin America Circulating Tumor Cells Market by Application
12.6.6 Brazil
12.6.6.1 Brazil Circulating Tumor Cells Market by Technology
12.6.6.2 Brazil Circulating Tumor Cells Market by Product
12.6.6.3 Brazil Circulating Tumor Cells Market by Specimen
12.6.6.4 Brazil Circulating Tumor Cells Market by Application
12.6.7 Argentina
12.6.7.1 Argentina Circulating Tumor Cells Market by Technology
12.6.7.2 Argentina Circulating Tumor Cells Market by Product
12.6.7.3 Argentina Circulating Tumor Cells Market by Specimen
12.6.7.4 Argentina Circulating Tumor Cells Market by Application
12.6.8 Colombia
12.6.8.1 Colombia Circulating Tumor Cells Market by Technology
12.6.8.2 Colombia Circulating Tumor Cells Market by Product
12.6.8.3 Colombia Circulating Tumor Cells Market by Specimen
12.6.8.4 Colombia Circulating Tumor Cells Market by Application
12.6.9 Rest of Latin America
12.6.9.1 Rest of Latin America Circulating Tumor Cells Market by Technology
12.6.9.2 Rest of Latin America Circulating Tumor Cells Market by Product
12.6.9.3 Rest of Latin America Circulating Tumor Cells Market by Specimen
12.6.9.4 Rest of Latin America Circulating Tumor Cells Market by Application

13 Company Profile
13.1 QIAGEN
13.1.1 Company Overview
13.1.2 Financials
13.1.3 Products/ Services Offered
13.1.4 SWOT Analysis
13.1.5 The SNS View
13.2 Bio-Techne Corporation
13.2.1 Company Overview
13.2.2 Financials
13.2.3 Products/ Services Offered
13.2.4 SWOT Analysis
13.2.5 The SNS View
13.3 Thermo Fisher Scientific Inc.
13.3.1 Company Overview
13.3.2 Financials
13.3.3 Products/ Services Offered
13.3.4 SWOT Analysis
13.3.5 The SNS View
13.4 Precision for Medicine
13.4 Company Overview
13.4.2 Financials
13.4.3 Products/ Services Offered
13.4.4 SWOT Analysis
13.4.5 The SNS View
13.5 AVIVA Biosciences
13.5.1 Company Overview
13.5.2 Financials
13.5.3 Products/ Services Offered
13.5.4 SWOT Analysis
13.5.5 The SNS View
13.6 BIOCEPT, Inc.
13.6.1 Company Overview
13.6.2 Financials
13.6.3 Products/ Services Offered
13.6.4 SWOT Analysis
13.6.5 The SNS View
13.7 Fluxion Biosciences Inc.
13.7.1 Company Overview
13.7.2 Financials
13.7.3 Products/ Services Offered
13.7.4 SWOT Analysis
13.7.5 The SNS View
13.8 Greiner Bio One International GmbH
13.8.1 Company Overview
13.8.2 Financials
13.8.3 Products/ Services Offered
13.8.4 SWOT Analysis
13.8.5 The SNS View
13.9 Ikonisys Inc.
13.9.1 Company Overview
13.9.2 Financials
13.9.3 Products/ Services Offered
13.9.4 SWOT Analysis
13.9.5 The SNS View
13.10 Miltenyi Biotec
13.10.1 Company Overview
13.10.2 Financials
13.10.3 Products/ Services Offered
13.10.4 SWOT Analysis
13.10.5 The SNS View
13.11 Menarini Silicon Biosystems
13.11.1 Company Overview
13.11.2 Financials
13.11.3 Products/ Services Offered
13.11.4 SWOT Analysis
13.11.5 The SNS View
13.11 LineaRx, Inc. (Vitatex, Inc.)
13.11.1 Company Overview
13.11.2 Financials
13.11.3 Products/ Services Offered
13.11.4 SWOT Analysis
13.11.5 The SNS View
13.11 STEMCELL Technologies, Inc.
13.11.1 Company Overview
13.11.2 Financials
13.11.3 Products/ Services Offered
13.11.4 SWOT Analysis
13.11.5 The SNS View

14. Competitive Landscape
14.1 Competitive Bench marking
14.2 Market Share Analysis
14.3 Recent Developments
14.3.1 Industry News
14.3.2 Company News
14.3.3 Mergers & Acquisitions

15. USE Cases and Best Practices

16. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone